期刊
EUROPEAN JOURNAL OF CANCER
卷 44, 期 1, 页码 46-53出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2007.08.028
关键词
mesothelioma; ovarian cancer; pancreatic cancer; lung cancer; tumour vaccine; monoclonal antibodies; clinical trial; CA-12; SS1P; MORAb-009
类别
资金
- Intramural NIH HHS [Z01 BC010510-04] Funding Source: Medline
- DIVISION OF BASIC SCIENCES - NCI [Z01BC010510] Funding Source: NIH RePORTER
- NATIONAL CANCER INSTITUTE [Z01BC010891, Z01BC010816] Funding Source: NIH RePORTER
Mesothelin is a tumour differentiation antigen that is normally present on the mesothelial cells lining the pleura, peritoneum and pericardium. It is, however, highly expressed in several huzman cancers including malignant mesothelioma, pancreatic, ovarian and lung adenocarcinoma. The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer. The limited mesothelin expression in normal tissues and high expression in many cancers makes it an attractive candidate for cancer therapy. Three mesothelin targeted agents are in various stages of clinical evaluation in patients. These include SS1P (CAT-5001) a recombinant immunotoxin targeting mesothelin, MORAb-009 a chimeric anti-mesothelin monoclonal antibody and CRS-207 a live-attenuated Listeria monocytogenes vector encoding human mesothelin. These ongoing clinical trials will help define the utility of mesothelin as a target for cancer therapy. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据